2D-QSAR, molecular docking, drug-likeness, and ADMET/ pharmacokinetic predictions of some non-small cell lung cancer therapeutic agents

Abstract

Objectives: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with nearly 2 million diagnoses and a 17% 5-year survival rate. The aim of this study was to use computer-aided techniques to identify potential therapeutic agents for NSCLC. Methods: The two dimensional-quantitative structure eactivity relationship (2D-QSAR) modeling was employed on some potential NSCLC therapeutic agents to develop a highly predictive model. Molecular dockingbased virtual screening were conducted on the same set of compounds to identify potential hit compounds. The pharmacokinetic features of the best hits were evaluated using SWISSADME and pkCSM online web servers, respectively. Results: The model generated via 2D-QSAR modeling was highly predictive with R2¼ 0.798, R2adj ¼ 0.754, Q2CV ¼ 0.673, R2 test ¼ 0.531, and cRp2 ¼ 0.627 assessment parameters. Molecular docking-based virtual screening identified compounds 25, 32, 15, 21, and 23 with the highest MolDock scores as the best hits, of which compound 25 had the highest MolDock score of 138.329 kcal/mol. All of the identified hits had higher MolDock scores than the standard drug (osimertinib). The best hit compounds were ascertained to be drug-like in nature following the Lipinski’s rule of five. Also, their ADMET features displayed average pharmacokinetic profiles. Conclusion: After successful preclinical testing, the hit compounds identified in this study may serve as potential NSCLC therapeutic agents due to their safety and efficacy with the exception of compound 23, which was found to be toxic. They can also serve as a template for designing novel NSCLC therapeutic agents.